Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancer
Johnson & Johnson announced Phase 3 PROTEUS substudy results showing perioperative ERLEADA (apalutamide) plus ADT reduced the risk of recurrence or death by 62% versus surgery alone in high-risk localized prostate cancer. The regimen also cut the risk of metastasis or death by 51% and the risk of needing subsequent therapy by 71%, with median event-free survival not reached versus 19.1 months for surgery alone.
Key figures
- Drug Name
- ERLEADA (apalutamide)
- Phase Of Trial
- Phase 3
- Patients randomized
- 408
- Grade 3 4 ae surgery
- 22%
- Median followup months
- 37.8
- Grade 3 4 ae apalutamide
- 31%
- Event free 3yr apalutamide
- 63%
- Event free 3yr surgery alone
- 41.4%
- Median efu surgery arm months
- 19.1
- Risk reduction subsequent therapy
- 71%
- Risk reduction metastasis or death
- 51%
- Risk reduction recurrence or death
- 62%
- Subsequent therapy free 3yr surgery
- 32%
- Subsequent therapy free 3yr apalutamide
- 64.6%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.